Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H23NO3 |
| Molecular Weight | 313.3915 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOc1ccccc1O[C@]([H])(c2ccccc2)[C@@]3([H])CNCCO3
InChI
InChIKey=CBQGYUDMJHNJBX-RTBURBONSA-N
InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
| Molecular Formula | C19H23NO3 |
| Molecular Weight | 313.3915 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment:: description was created based on several sources, including:
https://www.drugs.com/uk/reboxetine-4mg-tablets-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/11249515 | https://www.ncbi.nlm.nih.gov/pubmed/14647527
Curator's Comment:: description was created based on several sources, including:
https://www.drugs.com/uk/reboxetine-4mg-tablets-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/11249515 | https://www.ncbi.nlm.nih.gov/pubmed/14647527
Reboxetine is a selective noradrenergic reuptake inhibitor that acts by binding to the norepinephrine (NE) transporter and blocking reuptake of extracellular NE back into terminals. This compound has low affinity for other transporters and receptors. Reboxetine is used in acute treatment of depressive illness / major depression. Very common side effects are: difficulties to sleep (insomnia); dizziness; dry mouth; constipation; nausea (feeling sick); sweating. Based on studies conducted primarily outside the US, the FDA granted a preliminary letter of approval in 1999. However, more recent clinical studies conducted in the US and Canada, prompted by the FDA, resulted in a letter of non-approval.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Noradrenalin reuptake |
8.0 nM [IC50] | ||
Target ID: Serotonin reuptake |
1.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | EDRONAX Approved UseReboxetine is indicated for the acute treatment of depressive illness/major depression and for maintaining the clinical improvement in patients initially responding to treatment. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. | 1995 Aug |
|
| Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. | 1997 Apr |
|
| Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors. | 2002 Nov-Dec |
|
| Acute akinetic crisis with marked cognitive impairment due to Valproate treatment. | 2003 Apr |
|
| The promises and pitfalls of reboxetine. | 2003 Winter |
|
| Reboxetine may be helpful in the treatment of amphetamine withdrawal. | 2004 Jul |
|
| Reboxetine for the treatment of patients with Cocaine Dependence Disorder. | 2005 Apr |
|
| Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: neuroanatomical substrates for the antidepressant effect. | 2005 Jan |
|
| Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. | 2005 Nov |
|
| Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. | 2006 Jul |
|
| [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
| [Synthetic meshes for transvaginal surgical cure of genital prolapse: evaluation in 2005]. | 2006 Sep |
|
| [Advanced mesh implants for vaginal pelvic floor reconstruction: report of 100 prolift operations]. | 2007 Dec |
|
| Retrovesical haematoma after anterior Prolift procedure for cystocele correction. | 2007 Dec |
|
| Transvaginal repair of genital prolapse: preliminary results of a new tension-free vaginal mesh (Prolift technique)--a case series multicentric study. | 2007 Jul |
|
| [Prolift system in the correction of female genital prolapse]. | 2007 Sep |
|
| Laparoscopic sacral colpopexy with Gynemesh as graft material--experience and results. | 2007 Sep-Oct |
|
| Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. | 2008 |
|
| Complications and patient satisfaction after transobturator anterior and/or posterior tension-free vaginal polypropylene mesh for pelvic organ prolapse. | 2008 |
|
| Total Prolift System surgery for treatment posthysterectomy vaginal vault prolapse--do we treat both anatomy and function? | 2008 Dec |
|
| [Epidemiology and treatment for urinary incontinence and pelvic organ prolapse in women]. | 2008 Jul |
|
| Short-term outcome after transvaginal mesh repair of pelvic organ prolapse. | 2008 Jun |
|
| What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? | 2008 May |
|
| Reutilization of the Prolift mark system for the simultaneous correction of prolapse and incontinence in patients with pelvic organ prolapse and stress urinary incontinence. | 2008 Nov |
|
| [Choice of a surgical treatment of genital prolapse in women]. | 2008 Nov-Dec |
|
| [Clinical study on concomitant surgery for stress urinary incontinence and pelvic organ prolapse]. | 2008 Oct 15 |
|
| A prospective study to evaluate the anatomic and functional outcome of a transobturator mesh kit (prolift anterior) for symptomatic cystocele repair. | 2008 Sep-Oct |
|
| Implants in operative therapy in women with pelvic organ prolapse--two years of experience. | 2009 |
|
| Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
| The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. | 2009 |
|
| Outcome of treatment of anterior vaginal wall prolapse and stress urinary incontinence with transobturator tension-free vaginal mesh (prolift) and concomitant tension-free vaginal tape-obturator. | 2009 |
|
| Perineal approach to vascular anatomy during transobturator cystocele repair. | 2009 Apr |
|
| [Transvaginal repair of genital prolapse with Prolift: evaluation of safety and learning curve]. | 2009 Feb |
|
| De novo stress incontinence and pelvic muscle symptoms after transvaginal mesh repair. | 2009 Jul |
|
| Changes in levator ani muscle after vaginal hysterectomy and prolapse repair using the Total Prolift procedure. | 2009 Jul |
|
| [Clinical observation on quality of life of two different operative methods of total pelvic floor reconstruction.]. | 2009 Nov |
|
| Trocar-guided total tension-free vaginal mesh repair of post-hysterectomy vaginal vault prolapse. | 2009 Oct |
|
| Laparoscopic apical mesh excision for deep dyspareunia caused by mesh banding in the vaginal apex. | 2009 Sep |
|
| [Changes in the length of implanted mesh after reconstructive surgery of the anterior vaginal wall]. | 2010 Apr |
|
| [Prolene mesh comparing with sacrospinal fixation in the treatment of genital prolapse in women. Prospective multicentre randomized study]. | 2010 Apr |
|
| [Correlation between stress urinary incontinence or urgency and anterior compartment defect before and after surgical treatment]. | 2010 Apr |
|
| Transvaginal mesh repair of anterior and posterior vaginal wall prolapse: a clinical and ultrasonographic study. | 2010 Apr |
|
| Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use. | 2010 Apr |
|
| Permeation of chlorothalonil through nitrile gloves: collection solvent effects in the closed-loop permeation method. | 2010 Jul 15 |
|
| Mid-term results of pelvic organ prolapse repair using a transvaginal mesh: the experience in Sherbooke, Quebec. | 2010 Jun |
|
| Anatomical and functional outcomes of posterior intravaginal slingplasty for the treatment of vaginal vault or uterine prolapse: a prospective, multicenter study. | 2010 Mar |
|
| Optimal primary minimally invasive treatment for patients with stress urinary incontinence and symptomatic pelvic organ prolapse: tension free slings with colporrhaphy, or Prolift with the tension free midurethral sling? | 2010 May |
|
| [Postoperative pain after transvaginal repair of pelvic organ prolapse with or without mesh]. | 2010 Nov |
|
| Transurethral and suprapubic mesh resection after Prolift bladder perforation: a case report. | 2010 Oct |
|
| Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. | 2011 |
Sample Use Guides
8 mg a day (one 4 mg tablet twice a day). The maximum daily dose should not exceed 12 mg.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 15:11:07 UTC 2021
by
admin
on
Sat Jun 26 15:11:07 UTC 2021
|
| Record UNII |
947S0YZ36I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
656118
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
||
|
WHO-ATC |
N06AX18
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
||
|
WHO-VATC |
QN06AX18
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
71620-89-8
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
5858
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
127151
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
DB00234
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
REBOXETINE
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
M9514
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL14370
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
60842
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | RxNorm | ||
|
SUB15112MIG
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
C074679
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
C72838
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
98769-81-4
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
SUPERSEDED | |||
|
4808
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
71620-89-8
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
947S0YZ36I
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
2361
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
Reboxetine
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY | |||
|
7701
Created by
admin on Sat Jun 26 15:11:08 UTC 2021 , Edited by admin on Sat Jun 26 15:11:08 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Tmax | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||